Journal
JAMA ONCOLOGY
Volume 6, Issue 8, Pages 1271-1274Publisher
AMER MEDICAL ASSOC
DOI: 10.1001/jamaoncol.2020.2211
Keywords
-
Categories
Funding
- National Center for Advancing Translational Science [KL2TR002367]
- UNC Oncology Clinical Translational Research Training Program [K12CA120780]
Ask authors/readers for more resources
Question How have opioid prescribing patterns for Medicare patients changed during the opioid epidemic among generalists and oncologists? Findings In this cross-sectional study of the prescribing patterns of 251 820 generalists and 14 210 oncologists, analyzing Medicare Part D prescriber files, the annual adjusted mean rate of opioid prescriptions per 100 Medicare beneficiaries decreased from 68.2 to 49.7 among generalists (adjusted incidence rate ratio = 0.73) and from 77.8 to 58.8 among oncologists (adjusted incidence rate ratio = 0.76) between 2013 and 2017. Meaning Oncologists and generalists had similar trends in decreasing opioid prescription rates, raising concern that access to appropriate opioid-based cancer pain management may be inadvertently restricted during the opioid epidemic. Importance In response to the opioid epidemic, policies aiming to reduce opioid prescribing, misuse, and abuse may have the unintended consequence of restricting access to necessary opioid therapy for cancer-related pain. It is unknown how opioid prescribing patterns have changed among generalists and oncologists during this era. Objective To examine trends in opioid prescription rates for Medicare Part D beneficiaries from 2013 to 2017 among oncologists and generalists. Design, Setting, and Participants This repeated cross-sectional study of generalist physicians (internal medicine, family medicine, geriatric medicine, general practice) and oncology specialists (medical oncology, hematology-oncology, and radiation oncology) analyzed the Medicare Provider Utilization and Payment Data: Part D prescriber files from 2013 to 2017. Exposures Generalist vs oncology specialty. Main Outcomes and Measures Outcomes included physician-level rates of both opioid and long-acting opioid prescriptions per 100 Medicare Part D beneficiaries. Poisson regression was used to estimate annual predicted outcome rates and incidence rate ratios, adjusting for prescriber characteristics and state fixed effects. Results We analyzed the prescribing patterns of 251.820 generalists and 14.210 oncologists. From 2013 to 2017, the annual adjusted predicted mean rate of opioid prescriptions per 100 Medicare beneficiaries decreased from 68.2 to 49.7 among generalists (adjusted incidence rate ratio [aIRR] = 0.73; 95% CI, 0.73-0.73) and from 77.8 to 58.8 among oncologists (aIRR = 0.76; 95% CI, 0.74-0.77). The rate of long-acting opioid prescriptions per 100 Medicare beneficiaries also decreased from 8.0 to 5.4 for generalists (aIRR = 0.67; 95% CI, 0.66-0.68) and from 18.6 to 13.3 for oncologists (aIRR = 0.72; 95% CI, 0.69-0.74). Conclusions and Relevance We found large declines in opioid prescription rates for Medicare beneficiaries by generalists and oncologists from 2013 to 2017. Opioid policy and advocacy appear to have been effective in reducing the extent of opioid prescribing in the Medicare population. Similar declines between generalists and oncologists raise concern that access to cancer pain management may have been inadvertently restricted. How much of the decrease in prescribing by oncologists is appropriate vs inappropriate deserves further investigation. This cross-sectional study analyzed Medicare Part D prescriber files to determine changes in opioid prescribing patterns among oncologists and generalists between 2013 and 2017, during the opioid epidemic.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available